Conquering Debilitating Conditions Affecting Nervous Systems
OnusBio is an early stage biotechnology company
fully committed to developing innovative medicines to treat debilitating conditions affecting nervous systems. Our approach combines proven scientific knowledge, first-class data analytics, and fearless innovation.
Pipeline
OnusBio currently has two active programs in discovery and preclinical stages of development, marching towards to the completion of IND-enabling studies within two years.
Neuropathy
Throughout the history of medicine, pain has been among the most studied conditions. Current treatment options are often ineffective and can be highly addictive which is a serious public concern.
Our over arching goal is to develop new, non-addictive drug candidates to better manage neuropathic pain.
Traumatic Brain Injury (TBI)
TBI is a major healthcare concern. Unfortunately, current treatment options do not address the actual damage incurred to the brain itself leading to the continued destruction of neuronal and glial network long after the initial impact.
We are developing a drug candidate that engages with specific targets that are scientifically proven.
Leadership Team
Younok Dumortier Shin, PhD, MBA
Founder and CEO
George Nomikos,
MD, PhD
Chief Clinical Officer
Brian Shook,
PhD
Head of Research
Join our community on social media and be the first to hear about new insights, events, and announcements